



### **Quanta to Exhibit at the 56<sup>th</sup> Annual ERA-EDTA Congress**

**Alcester, Warwickshire, UK, 11 June 2019:** Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a pioneering British medical device company developing a personal haemodialysis system (SC+) for patient use in the clinic and the home, today announces that the Company will be exhibiting at the 56<sup>th</sup> Annual European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Congress which runs from Thursday 13<sup>th</sup> to Sunday 16<sup>th</sup> June, at the HUNGEXPO in Budapest, Hungary, at booth number 1.040.

Ahead of commercial launch, planned for Q4 2019, Quanta will be showcasing its updated, state-of-the-art personal haemodialysis system, SC+, designed to offer patients flexibility enabling them to fit treatment around everyday life.

SC+ maintains its small, compact form factor whilst offering patients the latest technology, including a high-resolution touch screen interface designed for simplicity, as well as capabilities enabling integration with digital health solutions.

If you would like to arrange a meeting with John E. Milad, Chief Executive Officer or Dr. Paul Komenda, Chief Medical Officer, please contact [enquiries@quantadt.com](mailto:enquiries@quantadt.com).

ERA-EDTA brings together worldwide physicians and kidney specialists to learn and share the latest advances in the field of clinical nephrology, dialysis, renal transplantation and related subjects.

**-ENDS-**

**For more information about Quanta, please contact:**

**Quanta**

John E. Milad,  
Chief Executive Officer

T: +44 (0)1789 400043  
E: [enquiries@quantadt.com](mailto:enquiries@quantadt.com)

**Consilium Strategic Communications**

Amber Fennell / Matthew Neal / Lindsey Neville

T: +44 (0)203 709 5708  
E: [quanta@consilium-comms.com](mailto:quanta@consilium-comms.com)

**About SC+**

SC+ is a small, simple and powerful haemodialysis system designed to provide greater flexibility around where, when and how patients manage and receive their dialysis therapy. As a CE marked medical device, SC+ has been successfully piloted with the NHS, demonstrating clinical efficacy and performance compatible with traditional treatment regimens used in-centre. The innovative and patented technology behind SC+ is based on a design breakthrough that allows all dialysate fluid management to be conducted on a small, lightweight, disposable cartridge. The small form factor and simple-to-use design are intended to enable a broader range of users—including patients themselves—to manage dialysis therapy delivery across a wide range of settings—from the clinic to the home.

**About Quanta**

Quanta aims to improve the lives of dialysis patients by providing advanced haemodialysis solutions for use both in the clinic and the home. Quanta's lead product SC+ is designed to empower dialysis patients by giving them greater flexibility, convenience and control over the delivery of their life-sustaining renal replacement therapy. Quanta is based in Alcester, UK, and was founded in 2008 as a spin out from IMI plc. The company has attracted funding from a group of leading investors, including: Wellington Partners, Seroba Life Sciences, b-to-v Partners, Stage Capital, ALIAD, CITA, Seventure Partners and Kuwait Life Sciences Company.

For more information, please visit: [www.quantadt.com](http://www.quantadt.com).

SC+ is not yet FDA cleared and not yet available for sale in the USA.